<table border="1" class="dataframe report-table" id="report-table">
  <thead>
    <tr style="text-align: right;">
      <th>diplotype</th>
      <th>activityscore</th>
      <th>phenotype</th>
      <th>ehrpriority</th>
      <th>drugid</th>
      <th>name</th>
      <th>drugrecommendation</th>
      <th>classification</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:10324</td>
      <td>tamoxifen</td>
      <td>Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).</td>
      <td>Strong</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:10689</td>
      <td>tramadol</td>
      <td>Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.</td>
      <td>Strong</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:1455099</td>
      <td>vortioxetine</td>
      <td>Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.</td>
      <td>Moderate</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:2670</td>
      <td>codeine</td>
      <td>Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.</td>
      <td>Strong</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:3247</td>
      <td>desipramine</td>
      <td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
      <td>Optional</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:32937</td>
      <td>paroxetine</td>
      <td>Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.</td>
      <td>Moderate</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:38400</td>
      <td>atomoxetine</td>
      <td>Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.</td>
      <td>Moderate</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:39786</td>
      <td>venlafaxine</td>
      <td>Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.</td>
      <td>Optional</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:42355</td>
      <td>fluvoxamine</td>
      <td>Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.</td>
      <td>Optional</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:5489</td>
      <td>hydrocodone</td>
      <td>Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.</td>
      <td>Optional</td>
    </tr>
    <tr>
      <td>CYP2D6: *19/*38</td>
      <td>CYP2D6: 0.0</td>
      <td>CYP2D6: Poor Metabolizer</td>
      <td>Abnormal/Priority/High Risk</td>
      <td>RxNorm:7531</td>
      <td>nortriptyline</td>
      <td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
      <td>Strong</td>
    </tr>
  </tbody>
</table>